leisure time -WSS

leisure time

author：focus 2025-09-28 15:56:49 - browse：9

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

focus

WSS

Ed Silverman on new gene therapies, biosimilars, coffee, and more

NIH study of ME/CFS points to clear biological hallmarks

Reporting on presidential health from Reagan to Trump and Biden

Dario to buy mental health app maker Twill in cash and stock deal

PBM reform efforts get punted in Congress

Elevance, SCAN deals highlight health insurer acquisition scrutiny

knowledge

leisure time

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Alabama frozen embryo ruling has major implications for IVF clinics

Trump demands the U.S. pay no more for drugs than other countries … again

Why palliative psychiatry is worth discussing

How one medical school became remarkably diverse

Dario to buy mental health app maker Twill in cash and stock deal

Peter Hotez and the public health issue of online harassment

Alabama hospital puts IVF treatments on hold

Medicare proposal to cover medical devices draws a mixed reaction

Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

PBM reform efforts get punted in Congress

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Reporting on presidential health from Reagan to Trump and Biden

Hospitals are piloting generative AI tools as regulators play catch

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

WATCH: Why do our ears pop?

Wikipedia

focus

focus

hotspot